IAMA Therapeutics
Entity

  • IAMA Therapeutics

    Created in 2021


  • To investigate (B)
    Some signals may appear as inconsistent with a regular activity

  • Social networks

    2,757

  • Activities

    biotech deeptech

  • Technologies

    Synthetic Biology

  • Entity types

    Startup

  • Location

    Genoa, Metropolitan City of Genoa, Italy

    Genoa

    Italy

  • Employees

    Scale: 2-10

    Estimated: 9

  • Engaged catalyst

    0
    0 0

  • Added in Motherbase

    1 year, 3 months ago
Description
  • Value proposition

    Our mission is to make a difference in the lives of individuals suffering from neurodevelopmental, cognitive disorders.

    IAMA Therapeutics is a clinical-stage pharmaceutical company raising a Series B to fund the clinical development of its lead candidate in epilepsy and neurodevelopment disorders. The Company’s lead candidate, IAMA-6, is a "best-in-class" selective NKCC1 inhibitor being developed for various orphan brain disorders, including drug-resistant epilepsy, and started the Phase 1 clinical trial in January 2024. Other pipeline candidates include new molecular entities to target Cation Chloride Cotransporters in pediatric neuropsychiatric conditions.

  • IAMA Therapeutics – Innovative Medicines for Brain Disorders

    Just another WordPress site

    • https://iamatherapeutics.com/
  • Website is possibly disabled or domain is for sale
Catalyst interactions
Catalyst Type Tweets Articles
No interactions
Social network dynamics
Similar entities
BETA
Last news
Show all articles